Summary of Cardiol Therapeutics FY Conference Call Company Overview - **Company**: Cardiol Therapeutics (NasdaqCM:CRDL) - **Focus**: Targeting inflammation in heart disease, particularly recurrent pericarditis and myocarditis, with a pipeline that includes late-stage and early-stage drug developments [2][3] Key Points Industry and Market Opportunity - **Heart Disease Landscape**: Heart failure is a significant health challenge, with a 50% five-year mortality rate, driven by obesity, diabetes, and hypertension [6] - **Market Potential**: Immunosuppressants for recurrent pericarditis are generating approximately $700 million annually, with forecasts suggesting they could reach $1 billion by 2028. Cardiol Therapeutics anticipates capturing a significant share of this market with its oral, non-immunosuppressive drug [19][20] Product Development - **Lead Program**: MAVERIC study focuses on recurrent pericarditis, with enrollment accelerating and significant near-term catalysts expected [4][5] - **Clinical Trials**: The Phase 2 program showed a 70% reduction in recurrence rates, and the ongoing Phase 3 trial is conservatively powered to achieve a 35%-40% reduction, which is considered a positive outcome by experts [32] - **ARCHER Trial**: Recent data from the ARCHER trial indicates a biological impact on myocarditis, which could open doors for new cardiovascular indications [20][21] Clinical Efficacy - **Pain Management**: In the Phase 2 trial, patients experienced a significant reduction in pericarditis pain, with 71% remaining recurrence-free during the study [13][14] - **C-Reactive Protein (CRP)**: Notable reduction in CRP levels, indicating a decrease in inflammation, was observed, with levels approaching normal by 8 weeks [12][14] - **Left Ventricular Mass**: The ARCHER trial demonstrated a significant reduction in left ventricular mass, correlating with improved cardiovascular outcomes [25][26] Regulatory and Commercialization Strategy - **FDA Alignment**: The company has received positive feedback from the FDA regarding the design of the MAVERIC trial, which could support a New Drug Application (NDA) upon successful outcomes [15][33] - **Market Positioning**: CardiolRx is positioned as a second-line treatment option, preferred by physicians due to its non-immunosuppressive nature and ease of access compared to existing therapies [34] Future Directions - **Next Generation Products**: CRD-38, a once-monthly subcutaneous formulation, is in development to address heart failure, targeting inflammation and fibrosis [28][30] - **Strategic Alliances**: The company is actively seeking partnerships to enhance its market presence and accelerate the development of its drug assets [4][30] Additional Insights - **Patient-Centric Approach**: The focus on oral medication and reducing dependency on immunosuppressants aligns with patient preferences for convenience and safety [10][34] - **Expert Collaboration**: The involvement of leading cardiovascular researchers and institutions enhances the credibility and potential success of Cardiol Therapeutics' clinical programs [18][23] This summary encapsulates the critical aspects of Cardiol Therapeutics' conference call, highlighting the company's strategic focus, product development, clinical efficacy, and market positioning within the heart disease landscape.

Financial Data and Key Metrics Changes - Fourth quarter revenue was $16 million, representing a 4% increase year-over-year, while full year revenue reached $56.7 million, reflecting a 10% growth [3][17] - Gross profit for the fourth quarter was $13.8 million, an increase of 8%, with gross margin rising to 86% from 83% a year ago [19] - Net loss for the fourth quarter was $11.9 million, or $0.46 per share, compared to a net loss of $10.7 million, or $0.43 per share in the prior year [22] Business Line Data and Key Metrics Changes - Revenue generated in the U.S. was $14.9 million, a 4% increase, with revenue units totaling 478, up from 460 in the prior year [17] - Revenue in Europe was $1.1 million, a 10% increase, with total revenue units rising to 49 from 41 [18] Market Data and Key Metrics Changes - The addressable market for Barostim therapy is estimated at $10.5 billion, with only less than 1% penetration [6] - The potential market could triple to approximately $30 billion if the BENEFIT-HF trial is successful, expanding the addressable patient population from 339,000 to over 980,000 [13] Company Strategy and Development Direction - The company focused on three strategic priorities: building a world-class sales organization, driving deep adoption in targeted centers, and reducing barriers to adoption [7] - The transition to Category I CPT codes is expected to improve patient access and reimbursement predictability, effective January 1, 2026 [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sales team's ability to execute the program-focused selling approach as they gain experience [8] - The initiation of the BENEFIT-HF trial is seen as a significant development that will enhance visibility and credibility in the heart failure community [25] Other Important Information - The company amended its debt facility to extend the maturity date to 2031 and provide access to additional capital [15][23] - The company expects total revenue for 2026 to be between $63 million and $67 million, with a gross margin between 84% and 86% [23][24] Q&A Session Summary Question: Can you talk about the initial sites for the BENEFIT-HF trial? - The trial will involve about 150 centers in the U.S. and some in Germany, with a mix of existing and new commercial sites [28] Question: How should we expect the growth of active accounts to trend through 2026? - The company expects to add around three active territories quarterly, leading to high single-digit account additions on a net basis each quarter in 2026 [31] Question: Do you see any scenario where the trial can be a tailwind for the core business? - Management believes there will be a goodwill effect and credibility boost from the trial, positively impacting the core business [35] Question: Can you share any anecdotal examples of how the Category I code has helped lower barriers to treatment? - Early signs show that payers who previously rejected prior authorizations are beginning to approve them, indicating positive progress [38] Question: What gives you confidence in the revenue guidance for 2026? - The company has seen sequential growth from Q1 to Q4 in 2025 and expects to return to growth after a seasonal dip from Q4 to Q1 [41] Question: How do you expect to manage the business to profitability over the medium term? - The company has sufficient cash reserves and plans to generate leverage by increasing sales productivity while managing expenses [75]

Company Overview - CVRx has developed the world's first autonomic neuromodulation therapy specifically for the treatment of heart failure, targeting a significant market opportunity valued at $10.5 billion based on prevalence [1] - The company aims to establish this therapy as the standard of care for heart failure treatment, supported by a well-defined patient population and a highly differentiated therapeutic approach [1] Industry Context - Heart failure is a major health issue affecting nearly 6.7 million Americans, leading to over 1 million hospital discharges and emergency room visits annually, along with more than 8 million physician visits [2] - The financial burden of heart failure is substantial, with costs projected to reach nearly $70 billion per year by the end of the decade [2] Treatment Landscape - Current treatment for heart failure typically involves a combination of four drugs known as quad therapy, which is the guideline-directed Class 1 treatment [3] - A small percentage of heart failure patients are evaluated for cardiac resynchronization therapy (CRT), indicating a limited scope for existing pacing therapies [3]

Core Insights - Karolinska Development's portfolio company AnaCardio has reported positive results from the phase 2a clinical trial GOAL-HF1 for the drug candidate AC01, aimed at treating heart failure with reduced ejection fraction (HFrEF) [1][5] - The study met its primary endpoint, demonstrating a favorable safety and tolerability profile, and showed encouraging efficacy signals, leading to plans for a phase 2b trial [1][5] Company Overview - AnaCardio AB is a privately held Swedish biopharmaceutical company focused on developing novel drugs for heart failure [2] - Karolinska Development holds a 10 percent ownership stake in AnaCardio [6] Clinical Trial Details - The phase 2a study enrolled 26 patients across 13 European heart failure centers, with participants receiving either 1 mg or 3 mg of AC01 or a placebo twice daily for 28 days [3] - Exploratory efficacy assessments indicated rapid and sustained improvements in haemodynamics and cardiac structure and function over the treatment period [3] - The pharmacokinetics of AC01 were predictable and dose-proportional, with confirmed target engagement through a dose-dependent increase in growth hormone release [4] Safety Profile - No treatment-emergent adverse events leading to discontinuation or serious adverse events were reported, nor were there any clinically relevant effects on blood pressure [5] - The CEO of Karolinska Development expressed confidence in AC01's potential to transform heart failure treatment based on the study's strong data [5]

Financial Data and Key Metrics Changes - Total expenses decreased by 35% year-over-year to $8.1 million in 2024 from $12.1 million in 2023, primarily driven by a 43% reduction in research and development expenses to $4.4 million from $7.7 million [35][36] - Net loss decreased to $7.9 million in 2024, down from $11.6 million in 2023, with net cash used in operations approximately $8 million, a 20% decrease from $10 million in 2023 [37][38] - The company ended the year with cash and cash equivalents totaling $2.4 million, with expectations of a moderate increase in cash burn in 2025 [38] Business Line Data and Key Metrics Changes - The CARDI-AMP Heart Failure Trial showed a 47% relative risk reduction in heart death equivalents and a 16% relative risk reduction in major adverse cardiac events, with a clinically meaningful 10.5% improvement in quality of life score [14][19] - The trial did not meet its primary endpoint due to the six-minute walk distance test, but showed strong results in other key areas [12][19] Market Data and Key Metrics Changes - The market reaction to the trial results was surprising, as the data was in line with expectations, indicating a strong need for therapies in ischemic heart failure [18][22] - The FDA granted cardiac cell therapy a breakthrough device designation, highlighting the significant unmet clinical need in this area [22][24] Company Strategy and Development Direction - The company is focused on advancing its cardiac cell therapy programs, with plans to share two-year data with the FDA and Japan's PMDA to align on pathways for making therapies available [21][22] - Ongoing discussions with regulatory agencies aim to ensure the safety and efficacy of cardiac cell therapy, with a focus on the unique benefits of the therapy compared to traditional medical devices [24][29] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strength of the data from the CARDI-AMP trial and its implications for future trials, particularly the CAR-DMHF2 trial [20][21] - The company anticipates modest increases in R&D expenses in 2025 as it continues to advance therapeutic candidates [36] Other Important Information - The company completed enrollment in the low-dose cohort of its cardi-allo-allogeneic mesenchymal stem cell therapy in ischemic heart failure [26] - The Helix biotherapeutic delivery platform is expected to enhance commercialization and clinical development efficiency [31][32] Q&A Session Summary Question: Can you provide more details on PMDA discussions in Japan? - Management met with PMDA in November and is preparing to share two-year data, which looks promising, potentially leading to conditional approval in Japan [42][43] Question: Were there any subsequent therapies that could have impacted the data read? - All patients were on guideline-directed medical therapy, and no other medications were introduced during the trial [46][48] Question: What is the expected timeline for sharing two-year data with the FDA? - The company is preparing a submission package and expects to request a consultation with the FDA soon, with timelines potentially ranging from three to eight weeks [78][80] Question: How does the data from the Heart Failure 1 trial inform the Heart Failure 2 trial? - The primary endpoint structure remains the same, and the company aims to replicate the positive outcomes seen in the first trial [88][90] Question: What are the next steps with the PMDA? - The company is finalizing the submission package and scheduling the next consultation with PMDA, aiming for a thorough and detailed presentation [78][82]

Financial Data and Key Metrics Changes - Total expenses decreased by 35% year-over-year to $8.1 million in 2024 from $12.1 million in 2023, primarily driven by a 43% reduction in research and development expenses to $4.4 million from $7.7 million [35][36] - Net loss decreased to $7.9 million in 2024, down from $11.6 million in 2023, and net cash used in operations was approximately $8 million, a 20% decrease from approximately $10 million in 2023 [37][38] - The company ended the year with cash and cash equivalents totaling $2.4 million, with expectations of a moderate increase in cash burn in 2025 [38] Business Line Data and Key Metrics Changes - The CARDI-AMP Heart Failure Trial data showed a 47% relative risk reduction in heart death equivalents and a 16% relative risk reduction in major adverse cardiac events [14][19] - Quality of life improvements were noted with a 10.5% point increase in quality of life scores and a 13.9-meter improvement in the six-minute walk distance test [14][15] Market Data and Key Metrics Changes - The market reaction to the trial results was unexpected, as the data was aligned with previous expectations despite not meeting the primary endpoint [18][19] - The company anticipates that the compelling data will enhance interest from distribution partners and strategics, particularly in the context of increasing attention on interventional therapies for heart failure [29] Company Strategy and Development Direction - The company is focused on advancing its lead therapeutic candidate, autologous cardiac cell therapy, and plans to share two-year data with regulatory authorities to align on pathways for making the therapy available [21][24] - Ongoing discussions with regulatory agencies aim to highlight the safety and efficacy of cardiac cell therapy, emphasizing the lack of long-term safety issues compared to traditional therapies [23][24] - The company is also progressing in other therapeutic programs, including the Cardi-AMP Cell Therapy and Chronic Myocardial Ischemia Trial [26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the strength of the two-year data and its potential impact on future trials and regulatory discussions [43][70] - The company is preparing a submission package for the PMDA in Japan, with expectations for a consultation meeting soon [78][82] - Management acknowledged the need for continued engagement with regulatory authorities to ensure a smooth approval process [81] Other Important Information - The company has completed enrollment in the low-dose cohort of its cardi-allo-allogeneic mesenchymal stem cell therapy in ischemic heart failure [26] - The Helix biotherapeutic delivery platform is expected to enhance future commercialization and clinical development efficiency [31][32] Q&A Session Summary Question: Can you provide more details on PMDA discussions in Japan? - Management met with PMDA in November and is preparing to share two-year data, which looks promising for potential conditional approval in Japan [42][43] Question: Were there any subsequent therapies that could have impacted the data read? - All patients were on guideline-directed medical therapy, and no other medications were introduced during the trial [47][50] Question: What is the expected timeline for sharing two-year data with the FDA? - The company is compiling the data for submission and expects to have a meeting with the FDA soon, with a timeline potentially as short as three weeks [70][82] Question: How does the data from Heart Failure 1 inform Heart Failure 2 trials? - The primary endpoint structure remains the same, and the company aims to replicate the positive outcomes observed in the first trial [88] Question: What are the next steps regarding interactions with the PMDA? - The company is preparing a submission package and scheduling a consultation meeting with the PMDA, with expectations for a timeline of three to eight weeks [78][82]

Financial Data and Key Metrics Changes - Nuwellis generated $2.3 million in revenue for Q4 2024, a 9% decrease year-over-year due to a decline in U.S. console sales and international sales, offset by a 21% increase in consumables utilization [10][20] - Gross margin improved to 58.4% for Q4 2024 compared to 54.4% in the prior year quarter, driven by higher manufacturing volumes of consumables and lower fixed overhead manufacturing expenses [21] - Net loss attributable to common shareholders in Q4 was $1.5 million, or a loss of $0.44 per share, compared to a net loss of $7.9 million, or a loss of $54.48 per share for the same period in 2023 [24][25] Business Line Data and Key Metrics Changes - The Critical Care business, the largest customer category, saw a 35% year-over-year quarterly revenue growth, benefiting from higher console sales and consumable utilization [11][20] - Heart failure and pediatric customer categories experienced declines of 36% and 20% respectively due to lower console sales [12][20] Market Data and Key Metrics Changes - The company reported nine new account wins throughout 2024, indicating positive market penetration [9] - A favorable reimbursement change effective January 1, 2025, allows Nuwellis to enter the outpatient services market for Aquadex technology, with the facility reimbursement fee increasing nearly fourfold from $413 to $1,639 per day [14][15] Company Strategy and Development Direction - Nuwellis aims to build its body of clinical evidence to make Aquadex Ultrafiltration therapy a standard of care and integrate it into medical society guidelines [12] - The company is focused on driving market penetration of Aquadex Ultrafiltration therapy, leveraging clinical evidence and increased reimbursement rates in the outpatient setting [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2025, highlighting the positive impact of new account wins and reimbursement changes on growth [9] - The recent publication in JACC: Heart Failure demonstrated a 60% reduction in heart failure events for patients treated with Aquadex compared to traditional IV diuretics, which is expected to support broader adoption of the technology [13][18] Other Important Information - The company had a voluntary recall of specific lots of blood circuit units, which resulted in a non-recurring expense of approximately $150,000 [22] - Total operating expenses decreased by approximately 25% compared to Q4 2023, reflecting savings from operational efficiency initiatives [24] Q&A Session Summary Question: Initial traction in the outpatient setting for Aquadex - Management noted that traction is beginning with several existing accounts needing to set up permanent outpatient facilities, with more activity expected in the coming month [29] Question: Number of Aquadex units sold in Q4 2024 and Q3 2024 - Three units were sold in Q4 2024, compared to 11 units in Q3 2024 [33][35] Question: Timing for reverse HF trial enrollment completion - Management indicated it is difficult to gauge the timing for enrollment completion [37] Question: Timing for the start of the Vivian clinical trial - Management provided a similar response, stating it is difficult to predict [39] Question: Changes in leadership and search for a new CEO - Management confirmed that a search firm has been hired and candidates are being evaluated, with no immediate need for major changes in direction [46]